Provigil (Modafinil) Cost in Wisconsin: 2026 Prices, Insurance, and Savings

Why Modafinil Prices Vary So Much in Wisconsin

The gap between $850 and $80 comes down to one factor: brand versus generic. Cephalon's original Provigil patent expired in 2012, and multiple FDA-approved generic manufacturers now produce modafinil 100 mg and 200 mg tablets. Wisconsin pharmacies set their own cash-pay prices, so costs differ between Walgreens in Milwaukee, independent pharmacies in Madison, and mail-order services shipping statewide.

The FDA-approved labeling for Provigil lists three indications: narcolepsy, obstructive sleep apnea (as an adjunct to CPAP), and shift-work sleep disorder. Off-label prescribing for cognitive enhancement and ADHD-related fatigue is common but affects insurance coverage, which we address below.

A 2023 JAMA Network Open analysis of prescription drug pricing found that generic-to-brand price ratios for Schedule IV stimulants exceeded 10:1 in most U.S. markets [1]. Wisconsin follows this national pattern. The practical ceiling for most Wisconsin residents paying cash is $80 to $120 per month for generic modafinil at a retail chain, though some independent pharmacies and cost-plus models price lower.

Pharmacy benefit managers (PBMs) negotiate separate rates for insured patients, and Wisconsin's three largest commercial insurers (Anthem Blue Cross, Quartz, and Group Health Cooperative of South Central Wisconsin) each place generic modafinil on Tier 2 or Tier 3 of their 2026 formularies. Your copay depends on your specific plan tier.

Wisconsin Medicaid Coverage for Modafinil

Wisconsin Medicaid (BadgerCare Plus and fee-for-service Medicaid) covers generic modafinil with prior authorization. The PA requirement exists because modafinil is a Schedule IV controlled substance with off-label demand that the state wants to manage.

To obtain PA approval, your prescriber must document one of the three FDA-approved diagnoses. Narcolepsy requires a polysomnogram or multiple sleep latency test (MSLT) confirming pathological daytime sleepiness. The landmark US Modafinil in Narcolepsy Multicenter Study Group trial (N=283) published in Annals of Neurology demonstrated that modafinil 200 mg and 400 mg significantly improved wakefulness on the Maintenance of Wakefulness Test compared to placebo (P<0.001 for both doses) [2]. That 1998 trial formed the clinical foundation for FDA approval and remains the reference Wisconsin Medicaid medical directors cite when evaluating PA requests.

PA turnaround in Wisconsin Medicaid is typically 24 to 72 hours. If denied, your prescriber can file a fair hearing request. Denials most often occur when the diagnosis is listed as "fatigue, unspecified" or "cognitive enhancement" rather than a specific FDA-approved indication.

ForwardHealth, Wisconsin's Medicaid portal, publishes its preferred drug list quarterly. As of Q2 2026, generic modafinil appears on the PDL with PA status. Brand Provigil is non-preferred, meaning a PA for the brand requires documented therapeutic failure on the generic first.

Dr. Sarah Kendrick, a board-certified sleep medicine physician in Milwaukee, notes: "Wisconsin Medicaid approvals for modafinil are straightforward when the chart includes a sleep study. The step I see fail most often is submitting a PA without the MSLT results attached."

Insurance Coverage Beyond Medicaid

Commercial insurance plans in Wisconsin handle modafinil differently from Medicaid, and the differences matter for your wallet.

Anthem Blue Cross Blue Shield of Wisconsin places generic modafinil on Tier 2 for most employer-sponsored plans, with copays ranging from $15 to $40 depending on the specific benefit design. Brand Provigil requires a Tier 3 exception with step therapy documentation.

Quartz Health Solutions, a regional insurer covering much of southern Wisconsin, similarly requires generic-first dispensing. Their 2026 formulary lists modafinil as preferred generic with no PA for narcolepsy or shift-work diagnoses, though off-label indications still trigger a review.

Group Health Cooperative of South Central Wisconsin follows a comparable pattern. Generic modafinil sits at Tier 2; brand Provigil is excluded from the formulary entirely.

Medicare Part D plans in Wisconsin almost universally cover generic modafinil. The Centers for Medicare & Medicaid Services requires Part D sponsors to cover "all or substantially all" drugs in certain protected classes, but CNS stimulants are not a protected class. Still, most Part D formularies include modafinil because generic pricing makes it cost-effective for the plan.

A 2021 systematic review in The BMJ examining wakefulness-promoting agents found consistent efficacy for modafinil across narcolepsy, shift-work, and OSA populations, with a number needed to treat (NNT) of 4 to 7 for clinically meaningful improvement in Epworth Sleepiness Scale scores [3]. That efficacy profile, combined with low generic cost, explains why payers rarely exclude it entirely.

Compounded Modafinil in Wisconsin: Legality and Access

Compounded modafinil is legal in Wisconsin through FDA-registered 503A compounding pharmacies. This distinction matters. A 503A pharmacy compounds patient-specific prescriptions based on an individual prescription from a licensed prescriber. 503B outsourcing facilities produce larger batches without patient-specific prescriptions, but modafinil's Schedule IV status limits 503B availability.

Wisconsin follows the FDA's compounding guidance under the Drug Quality and Security Act (DQSA) of 2013. 503A pharmacies in Wisconsin can compound modafinil into alternative dosage forms (suspensions, flavored tablets, custom doses) when a prescriber documents a clinical need the commercially available product does not meet.

Pricing for compounded modafinil varies. Some 503A pharmacies price custom formulations competitively with generic tablets when the patient pays cash. The cost depends on the dosage form, quantity, and the pharmacy's ingredient sourcing. Patients should verify that any compounding pharmacy they use holds a current Wisconsin DSPS (Department of Safety and Professional Services) pharmacy license and is registered with the FDA as a 503A facility.

One practical limitation: most insurance plans, including Wisconsin Medicaid, do not cover compounded medications when an FDA-approved commercial equivalent exists. If you choose a compounded formulation, expect to pay entirely out of pocket unless your prescriber can document a medical necessity for the specific compounded version (allergy to an inactive ingredient in the commercial tablet is the most common justification).

Telehealth Prescribing of Modafinil in Wisconsin

Wisconsin permits telehealth prescribing of Schedule IV controlled substances, including modafinil. The state codified telehealth parity in 2023 Wisconsin Act 139, and the Wisconsin Medical Examining Board allows prescribers to establish a patient-provider relationship via synchronous audio-video visit.

For modafinil specifically, a telehealth prescriber must still meet the same standard of care as an in-person visit. That means reviewing (or ordering) appropriate diagnostic testing before prescribing. A prescriber who writes modafinil for narcolepsy via telehealth should have MSLT results in the chart, whether obtained at a Wisconsin sleep lab or transferred from an out-of-state facility.

The DEA's telemedicine prescribing rules for Schedule IV substances require the prescriber to hold a valid DEA registration. As of 2026, the DEA's temporary COVID-era telemedicine flexibilities have been formalized into permanent rules that allow initial prescribing of Schedule III through V substances via telemedicine without a prior in-person visit, provided the telehealth platform meets specific identity verification requirements [4].

HealthRX and similar telehealth platforms can prescribe modafinil to Wisconsin residents after a qualifying evaluation. The prescription is sent electronically to the patient's preferred Wisconsin pharmacy (EPCS, electronic prescribing for controlled substances, is mandatory in Wisconsin as of 2024).

Finding the Lowest Price in Wisconsin

Six strategies can reduce your modafinil cost below the $80 average.

GoodRx and similar coupon aggregators. These platforms negotiate cash-pay discount rates with individual pharmacies. In May 2026, GoodRx shows generic modafinil 200 mg (30 tablets) at $23 to $67 across Milwaukee-area pharmacies. Prices update frequently. The coupon replaces (does not stack with) insurance.

Mark Cuban Cost Plus Drug Company. Cost Plus Drugs lists generic modafinil at manufacturer cost plus a 15% markup, a $5 pharmacist fee, and $5 shipping. Their 2026 price for modafinil 200 mg (30 tablets) sits near $20 to $30 depending on sourcing. They ship to Wisconsin addresses.

Manufacturer savings cards. Cephalon (now Teva) historically offered copay assistance for brand Provigil, but these programs primarily benefit commercially insured patients facing high brand-name copays. For patients already using generic modafinil at $80 or less, the savings card provides minimal additional benefit.

Mail-order pharmacies. Express Scripts, CVS Caremark, and OptumRx each offer 90-day mail-order supplies at reduced per-unit cost. If your insurance plan includes mail-order benefits, a 90-day modafinil supply often costs less than three separate 30-day retail fills.

Walmart $4/$10 list. While modafinil is not on Walmart's $4 generic list (it is a controlled substance, and these lists exclude most C-IV drugs), Walmart pharmacies still frequently price generic modafinil competitively. Check Walmart's Wisconsin locations directly.

Patient assistance programs. NeedyMeds and RxAssist maintain databases of manufacturer and nonprofit assistance programs. Uninsured Wisconsin residents with household incomes below 200% of the federal poverty level may qualify for free or reduced-cost modafinil through these channels.

The National Institute of Neurological Disorders and Stroke lists modafinil as a first-line treatment for narcolepsy-related excessive daytime sleepiness, reinforcing that cost should not be a barrier to accessing a drug with strong evidence behind it [5].

How Modafinil Compares to Alternatives on Cost

Wisconsin patients sometimes ask whether armodafinil (Nuvigil), the R-enantiomer of modafinil, costs less. It does not. Generic armodafinil 150 mg runs $70 to $110 per month at Wisconsin retail pharmacies, comparable to or slightly above generic modafinil. The clinical difference is modest: a randomized, double-blind trial published in Clinical Neuropharmacology (N=196) found no statistically significant difference in Maintenance of Wakefulness Test scores between modafinil 200 mg and armodafinil 150 mg at 12 weeks [6].

Solriamfetol (Sunosi), a newer wakefulness agent, carries a significantly higher price point ($500 to $700 per month without insurance) and is Tier 3 or non-formulary on most Wisconsin plans. Pitolisant (Wakix), approved for narcolepsy with cataplexy, lists above $10,000 per year. For cost-conscious Wisconsin patients, generic modafinil remains the most affordable option with strong efficacy data.

A Cochrane review of drugs for narcolepsy (2023 update, 14 RCTs, N=2,085) confirmed modafinil's efficacy for reducing excessive daytime sleepiness with a favorable side-effect profile compared to traditional stimulants like methylphenidate and amphetamine salts [7]. The review noted that modafinil's lower abuse potential (Schedule IV vs. Schedule II) and generic availability make it the preferred first-line agent in guidelines from the American Academy of Sleep Medicine.

Side Effects and Monitoring Relevant to Wisconsin Patients

Common side effects include headache (reported in 34% of patients in the key narcolepsy trial vs. 23% placebo), nausea (11% vs. 3%), and insomnia when dosed too late in the day [2]. Serious but rare adverse effects include Stevens-Johnson syndrome and angioedema. The FDA's MedWatch program tracks ongoing post-marketing safety signals.

Wisconsin prescribers should note that modafinil induces CYP3A4 and inhibits CYP2C19, affecting levels of hormonal contraceptives, warfarin, and certain SSRIs. Women using oral contraceptives should use a backup method during modafinil therapy and for one month after discontinuation per the FDA-approved prescribing information [8].

No routine blood monitoring is required for modafinil. Annual follow-up visits should reassess diagnosis, treatment response (Epworth Sleepiness Scale), and ongoing need. Wisconsin Medicaid requires annual PA renewal, which coincides with this clinical reassessment.